54103-36-5

Basic information

• Product Name: 1-(4-methoxyphenyl)-1,3-pentanedione
• Synonyms: 1-(4-methoxyphenyl)-1,3-pentanedione
• CAS NO: 54103-36-5
• Molecular Weight: 206.241
• Mol File: 54103-36-5.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 1-(4-methoxyphenyl)-1,3-pentanedione(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-methoxyphenyl)-1,3-pentanedione(54103-36-5)
• EPA Substance Registry System: 1-(4-methoxyphenyl)-1,3-pentanedione(54103-36-5)

Safety Data

• Hazardous Substances Data: 54103-36-5(Hazardous Substances Data)

Upstream product

• 105-37-3 Ethyl propionate 
• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 554-12-1 propanoic acid methyl ester 

Downstream Products

• 1477-19-6 benzarone 
• 3562-84-3 benzbromarone 
• 3343-80-4 (2-ethylbenzofuran-3-yl)(4-methoxyphenyl)methanone 
• 54103-42-3 1-(4-Methoxy-phenyl)-4,6-dimethyl-heptane-1,3,5-trione 
• 137795-09-6 3-(4-morpholinylmethyl)-5-ethyl-6-(4-methoxybenzoyl)-2,3-dihydropyrrolo[1,2,3-de]-1,4-benzoxazine 

Relevant articles and documents

Lewis Acid-Catalyzed Synthesis of Benzofurans and 4,5,6,7-Tetrahydrobenzofurans from Acrolein Dimer and 1,3-Dicarbonyl Compounds

2,3-Disubstituted benzofurans were synthesized from acrolein dimer and 1,3-dicarbonyl compounds by using N-bromosuccinimide as an oxidizing agent. The method was used to synthesize two commercial drug molecules, benzbromarone and amiodarone. The proposed mechanism of the reaction involves a N-bromosuccinimide (NBS)-assisted autotandem catalysis with Lewis acid catalyst. To proof the proposed mechanism, an intermediate was isolated successfully, which can be converted to 4,5,6,7-tetrahydrobenzofurans.

URAT1 inhibitor and its application

The invention discloses a URAT1 inhibitor compound and its application of the compound. The URAT1 inhibitor compound is the compound or its pharmaceutically acceptable salt shown in structure of Formula (I). The experiment shows that the compound provided

URAT1 inhibitor for promoting uric acid excretion

The invention belongs to the field of medicinal chemistry, and in particular relates to a URT1 inhibitor for promoting uric acid excretion, which is a compound represented by the structure of the formula (I) or a pharmaceutically acceptable salt thereof. Experiments show that the compound provided by the invention has excellent inhibitory effect to hURAT1 transport uric acid in HEK293 transfectedcells and has a good application prospect in treatment of hyperuricemia or gout. The formula (I) is shown in the description.